Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P16473: Variant p.Met453Thr

Thyrotropin receptor
Gene: TSHR
Feedback?
Variant information Variant position: help 453 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Methionine (M) to Threonine (T) at position 453 (M453T, p.Met453Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (M) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HTNA; sporadic; found in toxic thyroid nodules and hyperfunctioning thyroid adenomas. Any additional useful information about the variant.


Sequence information Variant position: help 453 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 764 The length of the canonical sequence.
Location on the sequence: help VFVLLILLTSHYKLNVPRFL M CNLAFADFCMGMYLLLIASV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         VFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASV

                              VFVLIVLLTSHYKLTVPRFLMCNLAFADFCMGMYLLLIASV

Mouse                         IFVLLILLTSHYKLTVPRFLMCNLAFADFCMGVYLLLIASV

Rat                           VFVLFVLLTSHYKLTVPRFLMCNLAFADFCMGVYLLLIASV

Pig                           VFVLVILLTSHYKLTVPRFLMCNLAFADFCMGMYLLLIASV

Bovine                        VFVLVILLTSHYKLTVPRFLMCNLAFADFCMGLYLLLIASV

Sheep                         VFVLVILLTSHYKLTVPRFLMCNLAFADFCMGLYLLLIASV

Cat                           VFVLIILLTSHYKLTVPRFLMCNLAFADFCMGMYLLLIASV
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 21 – 764 Thyrotropin receptor
Transmembrane 451 – 473 Helical; Name=2
Alternative sequence 254 – 764 Missing. In isoform Short.
Alternative sequence 275 – 764 Missing. In isoform 3.
Helix 448 – 477



Literature citations
A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism.
de Roux N.; Polak M.; Couet J.; Leger J.; Czernichow P.; Milgrom E.; Misrahi M.;
J. Clin. Endocrinol. Metab. 81:2023-2026(1996)
Cited for: VARIANT HTNA THR-453; Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
Parma J.; Duprez L.; van Sande J.; Hermans J.; Rocmans P.; van Vliet G.; Costagliola S.; Rodien P.; Dumont J.E.; Vassart G.;
J. Clin. Endocrinol. Metab. 82:2695-2701(1997)
Cited for: VARIANTS HYPERTHYROIDISM ASN-281; THR-281; THR-453; PHE-486; MET-486; THR-568; GLY-619; ILE-623; PHE-629; LEU-630; LEU-631; ILE-632; ALA-633; GLU-633; HIS-633; TYR-633 AND 658-ASN--ILE-661 DEL; Detection of thyroid-stimulating hormone receptor and G(s)alpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis.
Truelzsch B.; Krohn K.; Wonerow P.; Chey S.; Holzapfel H.-P.; Ackermann F.; Fuehrer D.; Paschke R.;
J. Mol. Med. 78:684-691(2001)
Cited for: VARIANTS ASN-281; ILE-425; THR-453; PHE-486; ASN-505; ARG-512; GLN-512; THR-568; GLY-619; VAL-623; LEU-631; ALA-632; ILE-632; GLU-633; HIS-633; TYR-633; ALA-639 AND PHE-656; CHARACTERIZATION OF VARIANTS ILE-425 AND GLN-512; Oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in the Japanese population.
Vanvooren V.; Uchino S.; Duprez L.; Costa M.J.; Vandekerckhove J.; Parma J.; Vassart G.; Dumont J.E.; van Sande J.; Noguchi S.;
Eur. J. Endocrinol. 147:287-291(2002)
Cited for: VARIANTS HYPERTHYROIDISM THR-453; MET-486; ARG-512 AND ALA-632;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.